Azenta's shares dropped 24.5% following the Q2 report as investors were disappointed by organic revenue decline, margin compression, and a cautious full-year outlook amid execution challenges and soft demand, particularly in North America.

• Organic revenue decreased 3% year-over-year in Q2, driven by weakened demand in North America and competitive pressures in Multiomics.
• Adjusted EBITDA margin fell to 5.4%, below expectations, reflecting lower volumes and operational inefficiencies.
• Continued strength was seen in recurring revenue areas, including sample repository solutions, product services, consumables, and instruments.
• Softness persisted in automated and cryogenic store systems, with ongoing quality remediation delays expected to extend into Q3.
• Fiscal 2026 guidance was lowered to organic revenue growth between -2% and +1%, with adjusted EBITDA estimated down 125 basis points to flat, citing prolonged capital deployment constraints and cautious demand.